Table 5.
Univariate Cox regression analysis for clinicopathological features and genotypes
| Variable | HR | DFS 95%CI | P value | HR | OS 95%CI | P value |
| Age < 65 yr | 1.513 | 0.873-2.621 | 0.140 | 1.229 | 0.682-2.213 | 0.492 |
| Rectal Ca | 1.550 | 0.890-2.703 | 0.121 | 1.282 | 0.713-2.306 | 0.406 |
| Stage III vs I%II | 2.532 | 1.368-4.695 | 0.003 | 1.877 | 1.009-3.494 | 0.047 |
| Grade III and IV vs I and II | 1.984 | 1.143-3.436 | 0.015 | 2.097 | 1.166-3.770 | 0.013 |
| KRAS mutation | 1.330 | 0.761-2.326 | 0.321 | 1.283 | 0.702-2.346 | 0.418 |
| BRAF V600E mutation | 1.276 | 0.310-5.255 | 0.736 | 2.743 | 0.845-8.902 | 0.093 |
| TYMS 5’UTR | 0.397 | 0.766 | ||||
| 2R | 1 | 1 | ||||
| 2R/3R | 1.213 | 0.498-2.958 | 0.671 | 0.745 | 0.332-1.672 | 0.475 |
| 3R | 1.690 | 0.678-4.213 | 0.260 | 0.846 | 0.355-2.020 | 0.707 |
| TYMS 5’UTR | 0.596 | 0.615 | ||||
| 2RG/3RG | 1 | 1 | ||||
| 2RG/2RG | 1.038 | 0.377-2.858 | 0.942 | 1.750 | 0.672-4.559 | 0.252 |
| 2RG/3RC | 1.523 | 0.684-3.394 | 0.303 | 1.625 | 0.702-3.760 | 0.257 |
| 3RC/3RC | 1.414 | 0.482-4.148 | 0.528 | 0.680 | 0.146-3.162 | 0.623 |
| 3RG/3RC | 2.128 | 0.902-5.018 | 0.085 | 1.782 | 0.686-4.625 | 0.235 |
| 3RG/3RG | 1.489 | 0.466-4.672 | 0.502 | 1.996 | 0.610-6.532 | 0.253 |
| TYMS 5’UTR | 0.204 | 0.589 | ||||
| 2RG/3RG | 1 | 1 | ||||
| 2RG/2RG | 1.702 | 0.343-8.441 | 0.515 | 3.322 | 0.787-14.03 | 0.102 |
| 2RG/3RC | 2.935 | 0.778-11.08 | 0.112 | 3.034 | 0.803-11.46 | 0.102 |
| 2RG/3RCLOH | 5.387 | 1.427-20.34 | 0.013 | 3.879 | 0.967-15.56 | 0.056 |
| 2RG/3RGLOH | 2.138 | 0.431-10.60 | 0.352 | 2.026 | 0.408-10.06 | 0.388 |
| 2RGLOH/3RC | 3.178 | 0.640-15.78 | 0.157 | 3.109 | 0.626-15.44 | 0.165 |
| 2RGLOH/3RG | 7.402 | 1.648-33.24 | 0.009 | 6.127 | 1.358-27.64 | 0.018 |
| 3RC/3RC | 4.326 | 1.031-18.15 | 0.045 | 1.733 | 0.288-10.42 | 0.548 |
| 3RG/3RC | 4.865 | 1.336-17.72 | 0.016 | 3.438 | 0.888-13.32 | 0.074 |
| 3RG/3RG | 3.413 | 0.761-15.30 | 0.109 | 3.994 | 0.887-17.99 | 0.071 |
| TYMS 5’UTR groups | 0.130 | 0.223 | ||||
| A1 | 1.136 | 0.574-2.251 | 0.714 | 1.882 | 0.917-3.861 | 0.085 |
| B2 | 1 | 1 | ||||
| C3 | 1.908 | 0.980-3.713 | 0.057 | 1.309 | 0.637-2.692 | 0.464 |
| TYMS 3’UTR | 0.791 | 0.846 | ||||
| del/del | 1.170 | 0.496-2.760 | 0.721 | 1.145 | 0.456-2.873 | 0.773 |
| ins/del | 1.244 | 0.664-2.329 | 0.495 | 1.219 | 0.622-2.387 | 0.564 |
| ins/ins | 1 | 1 | ||||
| TYMS 3’UTR | 0.299 | 0.391 | ||||
| del/del | 0.624 | 0.244-1.595 | 0.324 | 0.634 | 0.228-1.761 | 0.382 |
| del/LOH | 0.374 | 0.086-1.630 | 0.190 | 0.408 | 0.093-1.797 | 0.236 |
| ins/del | 0.634 | 0.329-1.224 | 0.175 | 0.743 | 0.372-1.482 | 0.399 |
| ins/LOH | 1 | 1 | ||||
| ins/ins | 0.417 | 0.172-1.016 | 0.054 | 0.391 | 0.140-1.087 | 0.072 |
| ins/ins vs ELSE | 0.593 | 0.267-1.318 | 0.200 | 0.511 | 0.201-1.297 | 0.158 |
| ins/LOH vs ELSE | 1.807 | 1.000-3.266 | 0.050 | 1.650 | 0.877-3.104 | 0.120 |
| ins/del vs ELSE | 0.976 | 0.556-1.713 | 0.933 | 1.131 | 0.626-2.044 | 0.684 |
| del/del vs ELSE | 0.964 | 0.411-2.262 | 0.934 | 0.907 | 0.358-2.299 | 0.837 |
| del/LOH vs ELSE | 0.565 | 0.137-2.327 | 0.430 | 0.570 | 0.138-2.359 | 0.438 |
| LOH | 1.480 | 0.833-2.629 | 0.181 | 1.350 | 0.732-2.487 | 0.336 |
| SNP G->C | 1.542 | 0.878-2.707 | 0.132 | 1.108 | 0.617-1.992 | 0.731 |
1
Low expression profile;
2
Medium expression profile;
3
High expression profile. DFS: Disease-free survival; OS: Overall survival; HR: Hazard ratios; CI: Confidence interval; Ca: Cancer; TYMS: Thymidylate synthase gene; UTR: Untranslated region; LOH: Loss of heterozygosity; 5FU: 5-fluorouracil; SNP: Single nucleotide polymorphism.